Effects of donepezil on DOI-induced head twitch response in mice: Implications for Tourette syndrome

Pharmacology Biochemistry and Behavior

Volumn 76, Issue 3-4, 2003, Pages 409-415

  Hayslett, Renee L ^a   Tizabi, Yousef ^a  

^a HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aricept; DOI; Donepezil; Head twitch; Mecamylamine; Nicotine; Tourette syndrome

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR; SEROTONIN 2A AGONIST; SEROTONIN 2C AGONIST;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; GILLES DE LA TOURETTE SYNDROME; HEAD TWITCH; MALE; MOTOR ACTIVITY; MOUSE; MOUSE STRAIN; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; SYMPTOM;

EID: 0345276539     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2003.08.015     Document Type: Article

References (38)

1. Aizenman E., Tang L., Reynolds I.J. Effects of nicotinic agonists on the NMDA receptor. Brain Res. 551:1991;355-357.
2. Baker G.B., Chokka P.R., Bornstein R.A. Neurochemical and some related psychopharmacological aspects of Tourette's syndrome: an update. J. Psychopharmacology. 9:1995;273-280.
3. Buisson B., Bertrand D. Nicotine addiction: the possible role of functional upregulation. Trends Pharmacol. Sci. 23:2002;130-136.
4. Burt T. Donepezil and related cholinesterase inhibitors as mood and behavioral controlling agents. Curr. Psychiatry Rep. 2:2000;473-478.
5. Court J.A., Piggott M.A., Perry E.K. Nicotine reduces the binding of [3H]MK-801 to brain membranes but not via the stimulation of high affinity nicotinic receptors. Brain Res. 524:1990;319-321.
6. Darmani N.A., Gerdes C.F. Temporal differential adaptation of head-twitch and ear-scratch responses following administration of challenge doses of DOI. Pharmacol. Biochem. Behav. 50:1995;545-550.
7. Darmani N.A., Shaddy J., Gerdes C.F. Differential ontogenesis of the DOI-induced behavior in mice. Physiol. Behav. 60:1996;1495-1500.
8. Dure L.S., Tucker D.M. Tourette syndrome. Curr. Opinion Neurology. 10:1997;153-159.
9. Dursun S.M., Handley S.L. Similarities in the pharmacology of spontaneous and DOI-induced head shakes suggest 5-HT2A receptors are active under physiological conditions. Psychopharmacology. 128:1996;198-205.
10. Dursun S.M., Reveley M.A., Bird R., Stirton R.F. Long lasting improvement of Tourette's syndrome with transdermal nicotine. Lancet. 344:1994;1577.
11. Fenster C.P., Whitworth T.L., Sheffield E.B., Quick M.W., Lester R.A. Upregulation of surface alpah4beta2 nicotinic receptors is initiated by receptor desensitization after chronic exposure to nicotine. J. Neurosci. 19:1999;4804-4814.
12. Gaynor C.M., Handley S.L. Effects of nicotine on head-shakes and tryptophan metabolites. Psychopharmacology. 153:2001;327-333.
13. Gentry C.L., Wilkins L.H. Jr., Lukas R.J. Effects of prolonged nicotinic ligand exposure on function of heterogeneously expressed, human alpha4beta2- and alpha4beta4-nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 304:2003;206-216.
14. Giacobini E., Zhu X.D., Williams E., Sherman K.A. The effect of the selective reversible acetylcholinesterase inhibitor E2020 on intracellular acetylcholine and bioorganic amine levels in rat cortex. Neuropharmacology. 35:1996;205-211.
15. Grottick A.J., Corrigall W.A., Higgins G.A. Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology. 157:2001;292-298.
16. Handley S.L., Dursun S.M. Serotonin and Tourette's syndrome: movements such as head-shakes and wet-dog shakes may model human tics. Adv. Biosci. 85:1992;235-253.
17. Hoopes S.P. Donepezil for Tourette's disorder and ADHD. J. Clin. Psychopharmacol. 19(4):1999;381-382.
18. Leckman J.F. Tourette's syndrome. Lancet. 360:2002;1577-1586.
19. Leckman J.F., Peterson B.S., Anderson G.M., Arnsten A.F.T., Pauls D.L., Cohen D.J. Pathogenesis of Tourette syndrome. J. Child Psychol. Psychiat. 38:1997;119-142.
20. Marks M.J., Grady S.R., Collins A.C. Downregulation of nicotinic receptor function after chronic nicotine infusion. J. Pharmacol. Exp. 1993;1268-1276.
21. McConville B.J., Fogelson M.H., Norman A.B., Klyklo W.M., Manderscheid P.Z., Parker K.W.et al. Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am. J. Psychiatry. 148:1991;793-794.
22. Pauls D.L., Raymond C.L., Stevenson J.M., Leckman J.F. A family study of Gilles de la Tourette syndrome. Am. J. Hum. Genet. 48:1991;154-163.
23. Peterson B.S., Leckman J.F. The temporal dynamics of tics in Gilles de la Tourette syndrome. Biol. Psychiatry. 44:1998;1337-1348.
24. Price R.A., Kidd K.K., Cohen D.J., Pauls D.L., Leckman J.F. A twin study of Tourette syndrome. Arch. Gen. Psychiatry. 42:1985;815-820.
25. Quick M.W., Lester R.A. Desensitization of neuronal nicotinic receptors. J. Neurobiol. 53:2002;457-478.
26. Sanberg P.R., McConville B.J., Fogelson H.M., Manderscheid P.Z., Parker K.W., Blythe M.M., Klykylo W.M., Norman A.B. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother. 43:1989;19-23.
27. Sanberg P.R., Silver A.A., Shytle R.D., Philipp M.K., Cagill D.W., Fogelson H.M.et al. Nicotine for the treatment of Tourette's syndrome. Pharmacol. Ther. 74:1997;21-25.
28. Shytle R.D., Silver A.A., Philipp M.K., McConville B.J., Sanberg P.R. Transdermal nicotine for Tourette's syndrome. Drug Dev. Res. 38:1996;290-298.
29. Silver A.A., Shytle R.D., Philipp M.K., Sanberg P.R. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J. Am. Acad. Child. Adolesc. Psychiatry. 35:1996;1631-1636.
30. Silver A.A., Shytle R.D., Philipp M.K., Wilkinson B.J., McConville B., Sanberg P.R. Transdermal nicotine and haloperidol in Tourette's disorder: a double-blind placebo-controlled study. J. Clin. Psychiatry. 62:2001;707-714.
31. Singer H.S. Neurobiology of Tourette syndrome. Neurol. Clin. N. Amer. 15:1997;357-379.
32. Storch A., Schrattenholz A., Cooper J.C., Abdel Ghani E.M., Gutbrod O., Weber K.H.et al. Physostigmine, galantamine and codeine act as "noncompetitive nicotinic receptor agonist" on clonal rat pheochromocytoma cells. Eur. J. Pharmacol. 290:1995;207-219.
33. Tizabi Y., Mastropaolo J., Park C.H., Riggs R.L., Powell D., Rosse R.B. et al. Both nicotine and mecamylamine block dizocilpine-induced explosive jumping behavior in mice: psychiatric implications. Psychopharmacology. 140:1998;202-205.
34. Tizabi Y., Copeland R.L., Brus R., Kostrzewa R.M. Nicotine blocks quinpirole-induced behavior in rats: psychiatric implications. Psychopharmacology. 145:1999;433-441.
35. Tizabi Y., Russell L.T., Johnson M., Darmani N.A. Nicotine attenuates DOI-induced head twitch response in mice: implications for Tourette syndrome. Prog. Neuropsychopharmacol. Biol. Psychiat. 25:2001;1445-1457.
36. Tizabi Y., Louis V.A., Taylor C.T., Waxman D., Culver K.E., Szechtman H. Effect of nicotine on quinpirole-induced checking behavior in rats: implications for obsessive-compulsive disorder. Biol. Psychiatry. 51:2002;164-171.
37. Zhang X., Gong Z.H., Nordberg A. Effects of chronic treatment with (+)- and (-)-nicotine on nicotinic acetylcholine receptors and N-methyl-D-aspartate receptors in rat brain. Brain Res. 644:1994;32-39.
38. Zhou F.M., Liang Y., Dani J.A. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat. Neurosci. 4:2001;1224-1229.